What is the difference between 505j application, 505b1 NDA & 505b2 NDA?
In this topic we will be discussing about 505j, 505b1 and 505b2 application and differences between all 3 applications. 505(j) Application A... Read More
+91-98 455 710 46 | info@nckpharma.com
Sign In
|Sign Up
Please sign in first
Not a member?
Please simply create an account before buying/booking any courses.
Create an account for free!
- Home
- NCK services
- Course List
- Admission
- Course Quick Glance
- Features of Online Courses
- Course Catalogue
- Course Application form
- Admission Notification & Special Offers
- Frequently asked question related to KPE courses
- Prospect Identification Process
- Final Examination Registration
- How to change / reset password?
- Course Upgrade
- Verify Course Certificate
- Request for Course Completion Certificate
- Corporate Training
- Knowledge Base
Tag
505(b)(1)
Our Popular Courses
Recent Articles
- What is the meaning of pharmaceutical profiling?
- What is phase zero study? What it’s significance?
- Sanofi-kymab-deal: Sanofi’s acquisition of a clinical-stage biopharmaceutical company Kymab
- Covishield received emergency use authorization in India
- Glenmark introducing Remogliflozin + Vildagliptin combination first time in India
- Myovant and Pfizer’s $4.2 Billion Deal for Orgovyx
- Insight on Aurobindo and COVAXX exclusive licensing agreement
- Pfizer, BioNTech covid vaccine approval tilldate
- Chugai received MHLW, Japan marketing authorization for humanized anti-PD-L1 monoclonal antibody, Tecentriq to treat unresectable advanced/recurrent NSCLC
- Lynparza received marketing authorization by MHLW, Japan to treat advanced ovarian, prostate and pancreatic cancers
- AstraZeneca – Alexion $39 billion deal
- UK approves Pfizer-BioNTech’s COVID-19 vaccine. Rollout in week time
- Saudi Arabia signs non-binding vaccine agreement with CureVac
- Telix Pharma to acquire TheraPharm GmbH
- Case Study: Clinical basis of MHLW approval of Astellas’s Evrenzo to treat anemia of CKD in adult patients not on dialysis
- Covid 19 Vaccine development and commercialization status | More than 50 vaccine candidate under development
- PostEra codevelopment deal with NeuroLucent for Alzheimer’s disease
- AbbVie, Eisai received new indication approval for Humira to treat pyoderma gangrenosum
- Pfizer submitted application for emergency use of Covid vaccine
- Take Self Competency Test in Esxport Documentation